OrthoPediatrics (NASDAQ:KIDS) Shares Gap Up on Analyst Upgrade

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) gapped up prior to trading on Tuesday after Truist Financial raised their price target on the stock from $35.00 to $38.00. The stock had previously closed at $33.60, but opened at $35.00. Truist Financial currently has a hold rating on the stock. OrthoPediatrics shares last traded at $35.44, with a volume of 160,769 shares trading hands.

Other equities research analysts have also issued research reports about the company. JMP Securities reaffirmed a “market outperform” rating and set a $50.00 price target on shares of OrthoPediatrics in a research report on Tuesday. Needham & Company LLC lifted their price target on shares of OrthoPediatrics from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday.

Insider Buying and Selling

In related news, insider Joseph W. Hauser sold 2,903 shares of OrthoPediatrics stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $28.06, for a total value of $81,458.18. Following the sale, the insider now owns 52,858 shares of the company’s stock, valued at $1,483,195.48. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Joseph W. Hauser sold 2,903 shares of OrthoPediatrics stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $28.06, for a total transaction of $81,458.18. Following the completion of the transaction, the insider now directly owns 52,858 shares in the company, valued at approximately $1,483,195.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark C. Throdahl sold 2,433 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $67,126.47. Following the sale, the director now owns 137,857 shares of the company’s stock, valued at $3,803,474.63. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,253 shares of company stock worth $477,375. 31.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Prime Capital Investment Advisors LLC bought a new position in OrthoPediatrics during the fourth quarter worth about $2,035,000. Vanguard Group Inc. boosted its stake in shares of OrthoPediatrics by 1.3% in the third quarter. Vanguard Group Inc. now owns 860,804 shares of the company’s stock valued at $27,546,000 after buying an additional 10,861 shares during the period. Blue Trust Inc. grew its position in OrthoPediatrics by 1.5% during the fourth quarter. Blue Trust Inc. now owns 28,670 shares of the company’s stock worth $917,000 after buying an additional 421 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in OrthoPediatrics by 0.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,731 shares of the company’s stock valued at $3,895,000 after acquiring an additional 549 shares in the last quarter. Finally, Conestoga Capital Advisors LLC lifted its position in shares of OrthoPediatrics by 24.0% during the 4th quarter. Conestoga Capital Advisors LLC now owns 45,353 shares of the company’s stock valued at $1,474,000 after acquiring an additional 8,770 shares during the period. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Trading Down 4.4 %

The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.90 and a current ratio of 5.44. The company has a market capitalization of $789.35 million, a price-to-earnings ratio of -36.06 and a beta of 1.16. The firm has a fifty day moving average price of $28.91 and a 200-day moving average price of $29.07.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The firm had revenue of $37.61 million for the quarter, compared to the consensus estimate of $37.59 million. OrthoPediatrics had a negative net margin of 14.10% and a negative return on equity of 5.03%. As a group, equities analysts anticipate that OrthoPediatrics Corp. will post -1.34 EPS for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.